Whilst the threshold of 7% was based on the current ADA treatment guidelines and is therefore clinically relevant, glycemic control improvements observed in patients not reaching target (or not meeting or exceeding a 1.0% reduction) were not captured in the analysis (e.g., a patient achieving an HbA1c of 7.1% would receive many benefits of improved glycemic control, but would not be classed as meeting the targets included in the present study)
The frustrating reality is that age-related decline in growth hormone, shifting thyroid function, creeping insulin resistance, and the hormonal turbulence of perimenopause or andropause can leave you feeling unwell long before a traditional lab panel raises a red flag
Quick reference comparing Primolut-N with three related hormonal options in our catalog by active ingredient, indication, and treatment role
Evidence-based shared-decision-making assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia
However, after consideration of public comments, we continue to believe these alternatives to be less useful than our proposals as they would either not meet the stated need to alert the public to the hospital's declaration of the accuracy and completeness of the data encoded within the MRF, or the attestation would not travel inside the MRF like the affirmation statement
Cardiovasc Diabetol 22(1):35
